Observation of the Effect of Low Molecular Weight Heparin Calcium Combined with Acetylcysteine in the Treatment of Idiopathic Interstitial Pneumonia
Abstract
Objective:Â To analyze the effect of low molecular weight heparin calcium combined with acetylcysteine in the treatment of patients with idiopathic interstitial pneumonia. Methods:Â The subjects selected for this study were patients with idiopathic interstitial pneumonia admitted to our hospital from June 2020 to June 2021, with a total of 56 cases. They were divided into control group and experimental group by random number table method. The control group was treated with acetylcysteine (28 cases), and the experimental group was treated with low molecular weight heparin calcium on the basis of the control group (28 cases). The treatment effects of the two groups were compared. Results:Â There were significant differences in the effective rates of treatment between the two groups, and the experimental group was higher (P<0.05). There were significant differences in pulmonary function indexes between the two groups, among which the experimental group was higher (P<0.05). Conclusion: Low molecular weight heparin calcium + acetylcysteine is effective in the treatment of patients with idiopathic interstitial pneumonia, and this combined treatment method can be promoted.
References
[2] Cheng MJ. Observation on the Effect of Low Molecular Weight Heparin Combined with Acetylcysteine in the Treatment of Idiopathic Interstitial Pneumonia [J]. Famous Doctors, 2020(04):243.
[3] Si SJ, He JD, Li YL. Observation on the Efficacy of Combined Acetylcysteine and Low Molecular Weight Heparin in the Treatment of Patients with Idiopathic Interstitial Pneumonia [J]. Internal Medicine, 2019, 14(04): 459-461.
Copyright (c) 2022 Rong Fan, Wei Xiao, Weihua Hu, Zhu Wu
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear
Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.